On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning technology to develop novel immunotherapies for a range of cancers and infectious diseases.

As part of the collaboration, BioNTech and InstaDeep formed a joint AI Innovation Lab in London, UK, and Mainz, Germany, to advance a portfolio of initiatives across drug discovery and design, protein engineering, manufacturing and supply chain optimization. The AI Innovation Lab combine InstaDeep’s advanced capabilities in the areas of artificial intelligence, machine learning, and digitalization along with BioNTech’s deep domain expertise in precision immunotherapies and its access to a wide variety of internal and external datasets.

One of the key research areas of the BioNTech-InstaDeep joint Innovation Lab is the development of next generation vaccines and biopharmaceuticals for the treatment of cancer and prevention and therapy of infectious diseases, including Covid-19.